Current guidelines recommend screening individuals with symptomatic CS or evidence of elevated serotonin exposure for CHD, and N-terminal pro-brain natriuretic peptide (proBNP) is considered the most useful biomarker for identifying CHD in CS patients [2]. Here, NPPB is linked to coronary artery disorder.